Anterior thalamic deep brain stimulation in refractory epilepsy: A randomized, double-blinded study

Area of Science:

• Neurology
• Neurosurgery
• Epileptology

Background:

• Pharmacoresistant epilepsy poses significant challenges in patient management.
• Deep brain stimulation (DBS) is an emerging therapeutic option for refractory epilepsy.
• Anterior thalamic nucleus (ANT) DBS has shown promise in previous studies.

Purpose of the Study:

• To evaluate the safety and efficacy of bilateral ANT DBS in patients with focal, pharmacoresistant epilepsy.
• To assess the impact of ANT DBS on seizure frequency and severity over a 12-month period.
• To compare outcomes between blinded and open stimulation phases.

Main Methods:

• A prospective, randomized, double-blinded study involving 18 patients with focal, pharmacoresistant epilepsy.
• Bilateral ANT electrodes were implanted, with antiepileptic treatment kept constant.
• Seizure frequency and Liverpool Seizure Severity Scale (LSSS) were used for outcome assessment.

Main Results:

• No significant difference in seizure frequency or LSSS between groups during the 6-month blinded phase.
• A significant 22% reduction in overall seizure frequency after 6 months of stimulation (P=0.009).
• Four patients experienced ≥50% reduction in total seizure frequency; 5 patients had ≥50% reduction in focal seizures.

Conclusions:

• ANT DBS is a safe treatment for severe, refractory epilepsy, supporting previous findings.
• The efficacy observed in this study is less pronounced than in some open-label studies.
• Further research may be needed to optimize ANT DBS parameters for maximal therapeutic benefit.